Clinical efficacy of irbesartan and amiodarone in elderly patients with paroxysmal atrial fibrillation

Journal of Central South University (Medical Sciences)

Volumn 33, Issue 9, 2008, Pages 871-874

  Cao, Dao Jun ^a   Mu, Chun Yan ^a   Tong, Feng ^a   Tang, Ri Bo ^b  

^a Department of Ophthalmology   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Amiodarone; Atrial fibrillation; Irbesartan

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; BIPHENYL DERIVATIVE; IRBESARTAN; TETRAZOLE DERIVATIVE;

AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG COMBINATION; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

AGED; AMIODARONE; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; BIPHENYL COMPOUNDS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; TETRAZOLES; TREATMENT OUTCOME;

EID: 53649111921     PISSN: 16727347     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Pedersen O D, Bagger H, Kober L, et al. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction[J]. Circulation, 1999, 100 (4): 376-380.
2. Shinagawa K, Derakhchan K, Nattel S. Pharmacological prevention of atrial tachycardia induced atrial remodeling as a potential therapeutic strategy[J]. Pacing Clin Eleetrophysiol, 2003, 26 (3): 752-764.
3. AFFIRM First Antiarrhythmic Drug Substudy Investigators. Maintenance of sinus rhythm in patients with atrial fibrillation: an AFFIRM substudy of the first antiarrhythmic drug[J]. J Am Coll Cardiol, 2003, 42 (1): 20-29.
4. Goette A, Arndt M, Rocken C, et al. Regulation of angiotensin II receptor subtypes during atrial fibrillation in humans[J]. Circulation, 2000, 101 (23): 2678-2681.
5. Kumagai K, Nakashima H, Urata H, et al. Effects of angiotensin II Type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation[J]. J Am Coll Cardiol, 2003, 41 (12): 2197-2204.
6. Hideko N, Koickiro K, Hidenori U, et al. Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation[J]. Circulation, 2000, 101 (22): 2612-2617.
7. Marcello D, Roberto L, Aldo P M, et al. Rationale and design of the GISSI-atrial fibrillation trial: a randomized, prospective, multicentre study on the use of valsartan, an angiotensin II AT1-receptorblocker, in the prevention of atrial fibrillation recurrence[J]. Ital Feder Cardiol, 2006, 7 (4): 29-38.
8. Kumagai K, Nakashima H, Urata H, et al. Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation[J]. J Am Coll Cardiol, 2003, 41 (12): 2197-2204.
9. Madrid A H, Bueno M G, Rebollo J M, et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study[J]. Circulation, 2002, 106 (3): 331-336.
10. Chinese source
11. YIN Yue-hui, LIU Zeng-zhang, WU Jin-jin, et al. Long-term clinical efficacy of losartan or Perindopril combination therapy with low-dose amiodarone in patients with paroxysmal atrial fibrillation[J]. Chin J Cardiol, 2006, 34 (4): 299-302.
12. Chinese source
13. YANG Jun, HUANG Cong-xin, JIANG Hong, et al. Electrophysiology of irbesartan in guinea pig ventricular myocytes[J]. Journal of the Fourth Military Medical University, 2005, 26 (1): 17-21.